Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper
Authors
Keywords
-
Journal
HEMATOLOGICAL ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2018-09-06
DOI
10.1002/hon.2540
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice
- (2018) John G. Gribben et al. BRITISH JOURNAL OF HAEMATOLOGY
- Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding
- (2018) Giuseppe Boriani et al. HEMATOLOGICAL ONCOLOGY
- Risk of tuberculosis in patients with solid cancers and haematological malignancies: a systematic review and meta-analysis
- (2017) Claudia C. Dobler et al. EUROPEAN RESPIRATORY JOURNAL
- PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma
- (2017) Benjamin L. Lampson et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions
- (2017) Rohit Loomba et al. GASTROENTEROLOGY
- Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach
- (2017) Iris de Weerdt et al. HAEMATOLOGICA
- Efficacy and safety of new direct antiviral agents in hepatitis C virus-infected patients with diffuse large B-cell non-Hodgkin's lymphoma
- (2017) Marcello Persico et al. HEPATOLOGY
- Hepatitis C virus reactivation in patients receiving cancer treatment: A prospective observational study
- (2017) Harrys A. Torres et al. HEPATOLOGY
- Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial
- (2017) Andrew D Zelenetz et al. LANCET ONCOLOGY
- Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells
- (2017) Mara Compagno et al. NATURE
- Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach
- (2017) Iris de Weerdt et al. HAEMATOLOGICA
- Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial
- (2017) Jeffrey A Jones et al. Lancet Haematology
- Idelalisib in the management of lymphoma
- (2016) C. Y. Cheah et al. BLOOD
- Follicular lymphoma: evolving therapeutic strategies
- (2016) B. S. Kahl et al. BLOOD
- Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
- (2016) B. L. Lampson et al. BLOOD
- Idelalisib-related pneumonitis
- (2016) Eglantine Haustraete et al. EUROPEAN RESPIRATORY JOURNAL
- Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients
- (2016) HAEMATOLOGICA
- Effect of Noninvasive Ventilation Delivered by Helmet vs Face Mask on the Rate of Endotracheal Intubation in Patients With Acute Respiratory Distress Syndrome
- (2016) Bhakti K. Patel et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pneumocystis jiroveciipneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients
- (2016) Catherine Cordonnier et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- ECIL guidelines for preventingPneumocystis jiroveciipneumonia in patients with haematological malignancies and stem cell transplant recipients
- (2016) Johan Maertens et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients
- (2016) HAEMATOLOGICA
- Idelalisib-associated Enterocolitis
- (2015) Christine Y. Louie et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Idelalisib-associated Colitis
- (2015) Anna-Sophie Weidner et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma
- (2015) C. Y. Cheah et al. BLOOD
- A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia
- (2015) S. M. O'Brien et al. BLOOD
- The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment
- (2015) F. Jin et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Clinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib
- (2015) Srinivasan Ramanathan et al. CLINICAL PHARMACOKINETICS
- American Gastroenterological Association Institute Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy
- (2015) K. Rajender Reddy et al. GASTROENTEROLOGY
- The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment
- (2015) Feng Jin et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Clinical drug interaction profile of idelalisib in healthy subjects
- (2015) Feng Jin et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Management of adverse events associated with idelalisib treatment: expert panel opinion
- (2015) Steven E. Coutré et al. LEUKEMIA & LYMPHOMA
- Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110 , for relapsed/refractory chronic lymphocytic leukemia
- (2014) J. R. Brown et al. BLOOD
- Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase- , as therapy for previously treated indolent non-Hodgkin lymphoma
- (2014) I. W. Flinn et al. BLOOD
- A phase 1 study of the PI3K inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)
- (2014) B. S. Kahl et al. BLOOD
- Consensus guidelines for diagnosis, prophylaxis and management ofPneumocystis jiroveciipneumonia in patients with haematological and solid malignancies, 2014
- (2014) L. Cooley et al. INTERNAL MEDICINE JOURNAL
- PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
- (2014) Ajay K. Gopal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hospital admissions/visits associated with drug-drug interactions: a systematic review and meta-analysis
- (2014) Supinya Dechanont et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Updated International Consensus Guidelines on the Management of Cytomegalovirus in Solid-Organ Transplantation
- (2013) Camille N. Kotton et al. TRANSPLANTATION
- An Official American Thoracic Society Clinical Practice Guideline: The Clinical Utility of Bronchoalveolar Lavage Cellular Analysis in Interstitial Lung Disease
- (2012) Keith C. Meyer et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- The determination and interpretation of the therapeutic index in drug development
- (2012) Patrick Y. Muller et al. NATURE REVIEWS DRUG DISCOVERY
- CAL-101, a p110 selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
- (2010) B. J. Lannutti et al. BLOOD
- Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
- (2010) S. E. M. Herman et al. BLOOD
- Altered Macrophage Function Contributes to Colitis in Mice Defective in the Phosphoinositide-3 Kinase Subunit p110δ
- (2010) Jennifer K. Uno et al. GASTROENTEROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now